NCCN Guidelines Reflect Recent Advances in Resectable NSCLCJune 2nd 2022
Updates to the NCCN guidelines for patients with resectable early-stage NSCLC now include neoadjuvant and adjuvant regimens with chemotherapy, immunotherapy, and targeted therapies, which promise to change biomarker testing practice.
FDA to Reassess Accelerated Immunotherapy ApprovalsMarch 12th 2021
Six indications for immune checkpoint inhibitors granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency continues an industry-wide evaluation of the pathway.
Abiraterone Lowers Risk of Death from Prostate Cancer in Two Clinical TrialsJune 6th 2017
According to findings presented at the 2017 ASCO Annual Meeting, earlier intervention with abiraterone acetate (Zytiga) lowered the risk of death by 40% for men with high-risk advanced or metastatic prostate cancer.
Shorter Adjuvant Chemo in Colon Cancer Is Effective, Reduces Neuropathy RiskJune 5th 2017
According to findings presented at the 2017 ASCO Annual Meeting, patients with low-risk advanced colon cancer would benefit from a reduction in chemotherapy post-surgery, without increasing risk of recurrence, to reduce risk of neuropathy.
Trial Examines Triplet Regimen in Ovarian CancerFebruary 14th 2017
In a current phase II/III clinical trial for patients with advanced, recurrent, platinum-resistant ovarian cancer, the novel agent fasbretablin tromethamine is combined with bevacizumab (Avastin) and either paclitaxel or pegylated liposomal doxorubicin.